Dasatinib in chronic myelogenous leukemia

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Base Sequence
  • Benzamides
  • Dasatinib
  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl / chemistry
  • Fusion Proteins, bcr-abl / genetics*
  • Genes, abl
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Mutation
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / chemistry
  • Pyrimidines / therapeutic use*
  • Thiazoles / chemistry
  • Thiazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • abl-bcr fusion protein, human
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib